ArticleAnnals of medicine and surgery (2012)2025
Hematological manifestations in systemic lupus erythematosus: a retrospective cross-sectional study from a tertiary care center in Nepal.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hematological abnormalities are common in systemic lupus erythematosus and anemia is the most common hematological manifestation. Studies investigating hematological disorders in Nepali SLE patients are lacking. This study is aimed to understand hematological abnormalities in South Asian population especially Nepali SLE patients. Methods: A descriptive cross-sectional study was conducted at a tertiary care center in Nepal after obtaining ethical approval from 2019 January to 2023 December. All the patients diagnosed based upon 2019 European League of Associations for Rheumatology and American College of Rheumatology (2019 EULAR/ACR) criteria were included in study excluding those with underlying blood disorders. Hospital records and electronic health records were reviewed retrospectively. A structured proforma was used to collect the data and Microsoft Excel was used for entering the data. Statistical Package for Social Sciences (SPSS) version 16.0 was used for descriptive analysis. Results: The mean age of 99 SLE patients was 29.31 ± 11.01 years (95% CI, 27.12-31.51). Females were 87 (87.88%) with 38 (38.38%) were of age group 21-30 years. Hematological abnormalities were present in 92 (92.92%) patients; anemia was present in 88 (88.89%) patients followed by lymphopenia, leukopenia, and thrombocytopenia in 56 (56.57%), 24 (24.24%), and 14 (14.14%) patients, respectively. Arthritis was present in 67 (67.68%) and mucocutaneous manifestations in 63 (63.63%) patients. Fifty-nine (59.60%) patients had renal involvement. Arthritis and renal involvement were common across all hematological abnormalities. Conclusion: Hematological abnormalities especially anemia is much more common than previously reported. Clinician should assess the hematological disorders in SLE patients. Prospective multicenter studies are required to relate organ involvement and hematological manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.